Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

from NYT > Health http://ift.tt/2vHlQNF
via health&fitness